|
AKAP2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.33569999797245E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.64340000052832E-07 |
| Normal-vs-Stage2 |
4.58519999746443E-08 |
| Normal-vs-Stage3 |
4.50779999994211E-08 |
| Normal-vs-Stage4 |
2.26540000092257E-08 |
| Stage1-vs-Stage2 |
2.253600E-01 |
| Stage1-vs-Stage3 |
2.651600E-01 |
| Stage1-vs-Stage4 |
1.385360E-01 |
| Stage2-vs-Stage3 |
6.946800E-01 |
| Stage2-vs-Stage4 |
8.554200E-01 |
| Stage3-vs-Stage4 |
5.275400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.5478000003899E-07 |
| Normal-vs-AfricanAmerican |
6.97529999982294E-07 |
| Normal-vs-Asian |
4.4951000033322E-08 |
| Caucasian-vs-AfricanAmerican |
9.016200E-01 |
| Caucasian-vs-Asian |
2.409000E-01 |
| AfricanAmerican-vs-Asian |
5.385000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.34680000485332E-08 |
| Normal-vs-Female |
1.27500000002279E-07 |
| Male-vs-Female |
2.955900E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.23289999998511E-07 |
| Normal-vs-Age(41-60Yrs) |
6.4831000012866E-08 |
| Normal-vs-Age(61-80Yrs) |
4.85189999288593E-09 |
| Normal-vs-Age(81-100Yrs) |
1.524230E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.269980E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.195900E-04 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.048200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.830400E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.451600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.625400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.384100E-02 |
| Classical-VS-Follicular |
1.79683000000042E-05 |
| Classical-VS-Other |
4.569600E-01 |
| Classical-VS-Normal |
4.36079999999173E-07 |
| Tall-VS-Follicular |
3.136800E-01 |
| Tall-VS-Other |
9.449400E-01 |
| Tall-VS-Normal |
3.30510000479123E-08 |
| Follicular-VS-Other |
5.364800E-01 |
| Follicular-VS-Normal |
2.34169994506317E-09 |
| Other-VS-Normal |
1.51203999999572E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.38970000454586E-08 |
| Normal-vs-N1 |
2.76339999771835E-08 |
| N0-vs-N1 |
7.872600E-01 |
|
|
